Business
0
Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again - Seeking Alpha
Novo Nordisk downgraded to Buy amid guidance cuts & competition. Explore its long-term obesity drug potential, strong pipeline & recovery outlook.
Comments